[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Regeneron Pharmaceuticals 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 USA

www.regeneron.com Employees: 15,410 P: 914-847-7000

Sector:

Medical

Description:

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

Key Statistics

Overview:

Market Capitalization, $K 80,625,248
Enterprise Value, $K 79,493,048
Shares Outstanding, K 105,720
Float, K 98,351
% Float 93.03%
Short Interest, K 3,501
Short Float 3.31%
Days to Cover 4.72
Short Volume Ratio 0.65
% of Insider Shareholders 6.97%
% of Institutional Shareholders 83.31%

Financials:

Annual Sales, $ 14,343 M
Annual Net Income, $ 4,505 M
Last Quarter Sales, $ 3,605 M
Last Quarter Net Income, $ 727,200 K
EBIT, $ 3,629 M
EBITDA, $ 4,173 M

Growth:

1-Year Return 37.51%
3-Year Return -0.50%
5-Year Return 24.85%
5-Year Revenue Growth 68.80%
5-Year Earnings Growth 23.90%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 14.29 on 07/30/26
Next Earnings Date 10/27/26
Earnings Per Share ttm 37.15
EPS Growth vs. Prev Qtr 67.07%
EPS Growth vs. Prev Year 16.88%
Annual Dividend & Yield (Paid) 3.64 (0.48%)
Annual Dividend & Yield (Fwd) 3.76 (0.51%)
Most Recent Dividend 0.940 on 05/20/26
Next Ex-Dividends Date 08/18/26
Dividend Payable Date 08/31/26
Dividend Payout Ratio 9.30%

REGN Ratios

Ratio
Price/Earnings ttm 18.95
Price/Earnings forward 358.42
Price/Earnings to Growth 29.50
Return-on-Equity % 13.47%
Return-on-Assets % 10.34%
Profit Margin % 31.41%
Debt/Equity 0.06
Price/Sales 5.44
Price/Cash Flow 17.59
Price/Book 2.46
Book Value/Share 297.23
Interest Coverage 120.42
60-Month Beta 0.24

REGN Dividends

Date Value
05/20/26 $0.9400
02/20/26 $0.9400
11/20/25 $0.8800
08/18/25 $0.8800
05/20/25 $0.8800
02/20/25 $0.8800
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.